0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Ustekinumab Therapy for Severe Interstitial Granulomatous Dermatitis With Arthritis

Pauline Leloup, MD; Hélène Aubert, MD; Sylvie Causse, MD; Benoît Le Goff, MD, PhD; Sébastien Barbarot, MD
JAMA Dermatol. 2013;149(5):626-627. doi:10.1001/jamadermatol.2013.256.
Text Size: A A A
Published online

Extract

Interstitial granulomatous dermatitis with arthritis (IGDA) is a rare disease that was first described by Ackerman1 in 1993. Fewer than 70 cases have been reported in the literature,2 and specific therapies are not available. We report here a case of severe recalcitrant IGDA that was successfully treated with ustekinumab.

Correspondence: Dr Leloup, Department of Dermatology, 1 Place Alexis Ricordeau, Nantes University Hospital, 44000 Nantes, France (pauline.leloup@hotmail.fr).

Conflict of Interest Disclosures: None reported.

Additional Contributions: We are indebted to E. Cassagnau, MD, pathologist at Nantes University Hospital, France.

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Graphic Jump Location

Figure 1. Disseminated violaceous plaques and papules on the thighs (A) and back (B).

Place holder to copy figure label and caption
Graphic Jump Location

Figure 2. Dermal infiltrate of histiocytes around foci of collagen degeneration.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 3. Complete skin remission after 6 months of ustekinumab treatment.

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

The Rational Clinical Examination EDUCATION GUIDES
Septic Arthritis

brightcove.createExperiences();